"I don't know the needs of the two competitors that are right now trying to talk to each other, but we don't see a need for a transformative M&A right now."

-Mike Doustdar, CEO of Ozempic maker Novo Nordisk in an interview with the Journal, referring to a recent Financial Times report that AstraZeneca and Bristol Myers Squibb held talks over a tie-up.